Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D8GVM1
|
|||
| Drug Name |
SAR443820
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Amyotrophic lateral sclerosis [ICD-11: 8B60.0; ICD-9: 335.2] | Phase 2 | [1] | |
| Company |
Sanofi
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Receptor-interacting protein 1 (RIPK1) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05237284) A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR443820 in Adult Participants With Amyotrophic Lateral Sclerosis, Followed by an Open-label Extension. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.